Disseminated Granuloma Annulare: Efficacy of Cyclosporine Therapy
Granuloma annulare is an anatomo-clinical entity that is frequently encountered in everyday dermatological practice. We report our experience regarding 4 patients with disseminated granuloma annulare. Each patient was treated with a cycle of cyclosporine therapy for six weeks. A cycle of systemic cy...
Gespeichert in:
| Veröffentlicht in: | International journal of immunopathology and pharmacology 2006-04, Vol.19 (2), p.433-438 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 438 |
|---|---|
| container_issue | 2 |
| container_start_page | 433 |
| container_title | International journal of immunopathology and pharmacology |
| container_volume | 19 |
| creator | Spadino, S. Altomare, A. Cainelli, G. Franchi, C. Frigerio, E. Garutti, C. Taglioni, M. Altomare, G.F. |
| description | Granuloma annulare is an anatomo-clinical entity that is frequently encountered in everyday dermatological practice. We report our experience regarding 4 patients with disseminated granuloma annulare. Each patient was treated with a cycle of cyclosporine therapy for six weeks. A cycle of systemic cyclosporine therapy was started at a dose of 4 mg/kg/day for four weeks, subsequently reduced by 0.5 mg/kg/day every two weeks. The clinical picture more or less completely resolved within three weeks in all of the patients, and there were no relapses during the dose-tapering period or the following 12 months. Cyclosporine was optimally tolerated by all four patients, none of whom experienced any therapy-related side effects. Cyclosporine is a valid therapeutic option for the treatment of disseminated granuloma annulare, although we recommend its use in a protected hospital environment that facilitates patient monitoring. |
| doi_str_mv | 10.1177/039463200601900219 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_68628396</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_039463200601900219</sage_id><sourcerecordid>68628396</sourcerecordid><originalsourceid>FETCH-LOGICAL-c341t-fb8c63cff02210d38688b0a3b02aa346cc44ab43e8389ab12e5f90889f648c983</originalsourceid><addsrcrecordid>eNp9kDtPwzAUhS0EolXpH2BAmdhCrx91r9mqUh5SJZYyW45rQ6okDnYz5N-TqpUYkJjuGb7zSfcQckvhgdLFYgZcCckZgASqABhVF2TMYI75gqO4JOMjkB-JEZmmtAcAClzMkV6TEZXIKQc1JsunMiVXl405uF32Ek3TVaE22bIZgonuMVt7X1pj-yz4bNXbKqQ2xLJx2fbLRdP2N-TKmyq56flOyMfzert6zTfvL2-r5Sa3XNBD7gu0klvvgTEKO44SsQDDC2DGcCGtFcIUgjvkqExBmZt7BYjKS4FWIZ-Q-5O3jeG7c-mg6zJZV1WmcaFLWqJkyJUcQHYCbQwpRed1G8vaxF5T0Mft9N_thtLd2d4Vtdv9Vs5LDcDsBCTz6fQ-dLEZvv1P-QPdJnV6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68628396</pqid></control><display><type>article</type><title>Disseminated Granuloma Annulare: Efficacy of Cyclosporine Therapy</title><source>Sage Journals GOLD Open Access 2024</source><creator>Spadino, S. ; Altomare, A. ; Cainelli, G. ; Franchi, C. ; Frigerio, E. ; Garutti, C. ; Taglioni, M. ; Altomare, G.F.</creator><creatorcontrib>Spadino, S. ; Altomare, A. ; Cainelli, G. ; Franchi, C. ; Frigerio, E. ; Garutti, C. ; Taglioni, M. ; Altomare, G.F.</creatorcontrib><description>Granuloma annulare is an anatomo-clinical entity that is frequently encountered in everyday dermatological practice. We report our experience regarding 4 patients with disseminated granuloma annulare. Each patient was treated with a cycle of cyclosporine therapy for six weeks. A cycle of systemic cyclosporine therapy was started at a dose of 4 mg/kg/day for four weeks, subsequently reduced by 0.5 mg/kg/day every two weeks. The clinical picture more or less completely resolved within three weeks in all of the patients, and there were no relapses during the dose-tapering period or the following 12 months. Cyclosporine was optimally tolerated by all four patients, none of whom experienced any therapy-related side effects. Cyclosporine is a valid therapeutic option for the treatment of disseminated granuloma annulare, although we recommend its use in a protected hospital environment that facilitates patient monitoring.</description><identifier>ISSN: 0394-6320</identifier><identifier>EISSN: 2058-7384</identifier><identifier>DOI: 10.1177/039463200601900219</identifier><identifier>PMID: 16831309</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Cyclosporine - therapeutic use ; Female ; Granuloma Annulare - drug therapy ; Granuloma Annulare - pathology ; Humans ; Immunosuppressive Agents - therapeutic use ; Male ; Middle Aged ; Skin - pathology</subject><ispartof>International journal of immunopathology and pharmacology, 2006-04, Vol.19 (2), p.433-438</ispartof><rights>2006 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c341t-fb8c63cff02210d38688b0a3b02aa346cc44ab43e8389ab12e5f90889f648c983</citedby><cites>FETCH-LOGICAL-c341t-fb8c63cff02210d38688b0a3b02aa346cc44ab43e8389ab12e5f90889f648c983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/039463200601900219$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/039463200601900219$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21945,27830,27901,27902,44921,45309</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/039463200601900219?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16831309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Spadino, S.</creatorcontrib><creatorcontrib>Altomare, A.</creatorcontrib><creatorcontrib>Cainelli, G.</creatorcontrib><creatorcontrib>Franchi, C.</creatorcontrib><creatorcontrib>Frigerio, E.</creatorcontrib><creatorcontrib>Garutti, C.</creatorcontrib><creatorcontrib>Taglioni, M.</creatorcontrib><creatorcontrib>Altomare, G.F.</creatorcontrib><title>Disseminated Granuloma Annulare: Efficacy of Cyclosporine Therapy</title><title>International journal of immunopathology and pharmacology</title><addtitle>Int J Immunopathol Pharmacol</addtitle><description>Granuloma annulare is an anatomo-clinical entity that is frequently encountered in everyday dermatological practice. We report our experience regarding 4 patients with disseminated granuloma annulare. Each patient was treated with a cycle of cyclosporine therapy for six weeks. A cycle of systemic cyclosporine therapy was started at a dose of 4 mg/kg/day for four weeks, subsequently reduced by 0.5 mg/kg/day every two weeks. The clinical picture more or less completely resolved within three weeks in all of the patients, and there were no relapses during the dose-tapering period or the following 12 months. Cyclosporine was optimally tolerated by all four patients, none of whom experienced any therapy-related side effects. Cyclosporine is a valid therapeutic option for the treatment of disseminated granuloma annulare, although we recommend its use in a protected hospital environment that facilitates patient monitoring.</description><subject>Cyclosporine - therapeutic use</subject><subject>Female</subject><subject>Granuloma Annulare - drug therapy</subject><subject>Granuloma Annulare - pathology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Skin - pathology</subject><issn>0394-6320</issn><issn>2058-7384</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDtPwzAUhS0EolXpH2BAmdhCrx91r9mqUh5SJZYyW45rQ6okDnYz5N-TqpUYkJjuGb7zSfcQckvhgdLFYgZcCckZgASqABhVF2TMYI75gqO4JOMjkB-JEZmmtAcAClzMkV6TEZXIKQc1JsunMiVXl405uF32Ek3TVaE22bIZgonuMVt7X1pj-yz4bNXbKqQ2xLJx2fbLRdP2N-TKmyq56flOyMfzert6zTfvL2-r5Sa3XNBD7gu0klvvgTEKO44SsQDDC2DGcCGtFcIUgjvkqExBmZt7BYjKS4FWIZ-Q-5O3jeG7c-mg6zJZV1WmcaFLWqJkyJUcQHYCbQwpRed1G8vaxF5T0Mft9N_thtLd2d4Vtdv9Vs5LDcDsBCTz6fQ-dLEZvv1P-QPdJnV6</recordid><startdate>20060401</startdate><enddate>20060401</enddate><creator>Spadino, S.</creator><creator>Altomare, A.</creator><creator>Cainelli, G.</creator><creator>Franchi, C.</creator><creator>Frigerio, E.</creator><creator>Garutti, C.</creator><creator>Taglioni, M.</creator><creator>Altomare, G.F.</creator><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20060401</creationdate><title>Disseminated Granuloma Annulare: Efficacy of Cyclosporine Therapy</title><author>Spadino, S. ; Altomare, A. ; Cainelli, G. ; Franchi, C. ; Frigerio, E. ; Garutti, C. ; Taglioni, M. ; Altomare, G.F.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c341t-fb8c63cff02210d38688b0a3b02aa346cc44ab43e8389ab12e5f90889f648c983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Cyclosporine - therapeutic use</topic><topic>Female</topic><topic>Granuloma Annulare - drug therapy</topic><topic>Granuloma Annulare - pathology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Skin - pathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Spadino, S.</creatorcontrib><creatorcontrib>Altomare, A.</creatorcontrib><creatorcontrib>Cainelli, G.</creatorcontrib><creatorcontrib>Franchi, C.</creatorcontrib><creatorcontrib>Frigerio, E.</creatorcontrib><creatorcontrib>Garutti, C.</creatorcontrib><creatorcontrib>Taglioni, M.</creatorcontrib><creatorcontrib>Altomare, G.F.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of immunopathology and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Spadino, S.</au><au>Altomare, A.</au><au>Cainelli, G.</au><au>Franchi, C.</au><au>Frigerio, E.</au><au>Garutti, C.</au><au>Taglioni, M.</au><au>Altomare, G.F.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disseminated Granuloma Annulare: Efficacy of Cyclosporine Therapy</atitle><jtitle>International journal of immunopathology and pharmacology</jtitle><addtitle>Int J Immunopathol Pharmacol</addtitle><date>2006-04-01</date><risdate>2006</risdate><volume>19</volume><issue>2</issue><spage>433</spage><epage>438</epage><pages>433-438</pages><issn>0394-6320</issn><eissn>2058-7384</eissn><abstract>Granuloma annulare is an anatomo-clinical entity that is frequently encountered in everyday dermatological practice. We report our experience regarding 4 patients with disseminated granuloma annulare. Each patient was treated with a cycle of cyclosporine therapy for six weeks. A cycle of systemic cyclosporine therapy was started at a dose of 4 mg/kg/day for four weeks, subsequently reduced by 0.5 mg/kg/day every two weeks. The clinical picture more or less completely resolved within three weeks in all of the patients, and there were no relapses during the dose-tapering period or the following 12 months. Cyclosporine was optimally tolerated by all four patients, none of whom experienced any therapy-related side effects. Cyclosporine is a valid therapeutic option for the treatment of disseminated granuloma annulare, although we recommend its use in a protected hospital environment that facilitates patient monitoring.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>16831309</pmid><doi>10.1177/039463200601900219</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 0394-6320 |
| ispartof | International journal of immunopathology and pharmacology, 2006-04, Vol.19 (2), p.433-438 |
| issn | 0394-6320 2058-7384 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68628396 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Cyclosporine - therapeutic use Female Granuloma Annulare - drug therapy Granuloma Annulare - pathology Humans Immunosuppressive Agents - therapeutic use Male Middle Aged Skin - pathology |
| title | Disseminated Granuloma Annulare: Efficacy of Cyclosporine Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T13%3A18%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disseminated%20Granuloma%20Annulare:%20Efficacy%20of%20Cyclosporine%20Therapy&rft.jtitle=International%20journal%20of%20immunopathology%20and%20pharmacology&rft.au=Spadino,%20S.&rft.date=2006-04-01&rft.volume=19&rft.issue=2&rft.spage=433&rft.epage=438&rft.pages=433-438&rft.issn=0394-6320&rft.eissn=2058-7384&rft_id=info:doi/10.1177/039463200601900219&rft_dat=%3Cproquest_AFRWT%3E68628396%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68628396&rft_id=info:pmid/16831309&rft_sage_id=10.1177_039463200601900219&rfr_iscdi=true |